The estimated Net Worth of David Setboun is at least $15.4 Тысяча dollars as of 16 July 2020. Mr. Setboun owns over 5,000 units of Brainstorm Cell Therapeutics stock worth over $15,400 and over the last 5 years he sold BCLI stock worth over $0. In addition, he makes $0 as Chief Operating Officer и Executive Vice President at Brainstorm Cell Therapeutics.
David has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BCLI stock worth $64,750 on 16 July 2020.
The largest trade he's ever made was buying 5,000 units of Brainstorm Cell Therapeutics stock on 16 July 2020 worth over $64,750. On average, David trades about 2,500 units every 0 days since 2020. As of 16 July 2020 he still owns at least 55,000 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Mr. Setboun stock trades at the bottom of the page.
David Setboun has been appointed as Chief Operating Officer, Executive Vice President of the Company effective 4/7/2020. International pharmaceutical executive Dr. Setboun, has directed commercial development, business strategy, and product launches for 2 decades at 3 major biopharmaceutical companies. Most recently, Dr. Setboun served as VP Corporate Development, Strategy & Business at Life Biosciences. In this role, David was instrumental in the development of various critical commercial, operating and funding milestones. From June 2015 to June 2018, he served as President, Biogen, France where he launched Biogen's rare disease franchise. In addition, he supervised the launch of key neurology products and oversaw the Biosimilar business unit. Prior to his tenure at Biogen, Dr. Setboun, served as President, AstraZeneca, Portugal from 2012 to 2015, where he managed a product portfolio that grossed over $200 million annually. Prior to this role, David led the European Sales & Marketing function as AstraZeneca's VP Europe where he directed a team of executives in marketing, commercial excellence, pricing and market access. During his tenure, he expanded AstraZeneca's Oncology, Diabetes and Cardiovascular franchises. From 2002 to 2009, Dr. Setboun directed national and international teams and projects for Eli Lilly and Company in France and the USA. Fluent in French, English, Spanish and Portuguese, Dr. Setboun received his Pharmaceutical Doctorate (Pharm.D.) from University Paris XI in 1997 and his MBA from H.E.C Paris in 2001. More recently, David graduated from Harvard Business School (AMP 194).
David Setboun is 45, he's been the Chief Operating Officer и Executive Vice President of Brainstorm Cell Therapeutics since 2020. There are 15 older and 3 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.
David's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger и International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: